SII Halts COVID-19 Vaccine Production Amid Low Demand
The Serum Institute of India has halted the production of the Covishield (AstraZeneca) vaccine amid a glut of vaccine supplies. The SII's stockpile of vaccines has swelled to 200 million doses. The export of Covid vaccines had been earlier restricted, but resumed in November last year. The SII had recently appealed to the government to cut the gap between the second dose and the "precautionary" dose to just six months.